drugset

drugset / Trial / NCT04312750

Adhesion of Lidocaine Topical System 1.8%

NCT04312750 ↗

Phase 1 Completed 54 enrolled Scilex Pharmaceuticals, Inc.

NaSingle-groupOpen-labelOther

Summary

The objective of this study is to evaluate the adhesion performance of ZTlido (lidocaine topical system) 1.8% in normal, healthy volunteers.

Timeline

Start: 2015-12
Primary completion: 2015-12
Completion: 2015-12

Publications

Gudin J, Webster LR, Greuber E, Vought K, Patel K, Kuritzky L. Open-Label Adhesion Performance Studies of a New Lidocaine Topical System 1.8% versus Lidocaine Patches 5% and Lidocaine Medicated Plaster 5% in Healthy Subjects. J Pain Res. 2021 Feb 23;14:513-526. doi: 10.2147/JPR.S287153. eCollection 2021.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lidocaine	Other / unclassified	36 mg	Topical

Indications

No indication recorded.